Clinical trials
Psychosis clinical trials
Below are recruiting psychosis clinical trials, each written for real people, not researchers. We’re tracking 145 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07225179Recruiting
Mobile help for caregivers of young adults with early psychosis
This study tests a mobile app (Bolster) designed to support caregivers of young adults who have recently experienced psychosis. It aims to provide resources and connections to help you care for your loved one and yourself.
Chapel Hill, North CarolinaAges 18 years+ - NCT06540833RecruitingPhase 2
Study of ITI-1284 for psychosis in Alzheimer's disease
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
Anaheim, CaliforniaAges 55 years+ - NCT07226895RecruitingPhase 1/Phase 2
Study of MT1988 for people at high risk for psychosis
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Irvine, CaliforniaAges 17–30 - NCT07747181Recruiting
Brain stimulation and yoga for thinking skills in psychosis
This study tests whether combining brain stimulation with yoga can improve thinking and memory in people with psychosis. It may help with daily functioning and quality of life.
Hung Hom, KowloonAges 18–65 - NCT06224530Recruiting
Testing levetiracetam's effect on brain function in psychosis risk
This trial tests whether a single dose of levetiracetam, a medication that affects brain chemistry, can change brain function and thinking in people at risk for psychosis. The goal is to see if it might help prevent symptoms from worsening.
London, LondonAges 18–40 - NCT07417904Recruiting
Brave program for safety and violence risk in early psychosis
This trial tests a program called BRAVE to help young people with early psychosis learn skills to stay safe and reduce violence risk. It is for those already getting care at a clinic and considered stable enough to participate.
Washington D.C., District of ColumbiaAges 16–30 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT07716969Recruiting
Reducing time without treatment for psychosis
This trial tests a program to help people get treatment faster for psychosis. It is for patients who have started OPUS treatment within the last 9 months and may have a schizophrenia-related condition.
Copenhagen, DenmarkAges 18–35 - NCT04411225RecruitingPhase 3
CBD may help early psychosis along with usual treatment
This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.
La Jolla, CaliforniaAges 16–30 - NCT04789915RecruitingPhase 1
Testing memantine added to dopamine-targeting treatment for early psychosis
This Phase 1 study tests whether adding memantine can improve “negative symptoms” (like low motivation, reduced emotional expression) in people having their first episode of psychosis. It’s designed to understand safety and early effects when dopamine-related treatment is adjusted.
Glostrup Municipality, Capitol RegionAges 18–45 - NCT05131035Recruiting
Trial for thinking-speed training to lower psychosis risk
This study targets problems with “processing speed,” or how fast your brain handles information, to see if it can improve social functioning and lower the risk of developing full psychosis. It’s for people who are considered at high risk for psychosis but do not already have schizophrenia.
Glen Oaks, New YorkAges 14–20 - NCT05365347Recruiting
Program to reduce risky alcohol use in early psychosis
This study tests an intervention aimed at helping people with early psychosis who also drink in a risky way. It may help reduce problematic drinking during a critical early period of illness.
Halifax, Nova ScotiaAges 16–35 - NCT05440214Recruiting
Therapy to reduce suicide risk in people with psychosis
This trial tests an approach aimed at emotional ups-and-downs to help lower suicide risk in people who have psychosis and are at higher risk for suicidal thoughts or behaviors. If you qualify, you would get outpatient mental health care while participating in the study.
Baltimore, MarylandAges 18 years+ - NCT05445180Recruiting
Brain scan study of thinking in cannabis users with psychosis
This study uses brain imaging to understand how thinking works in people who use cannabis, comparing those with psychosis to people without psychosis. It may help researchers learn what brain patterns relate to thinking difficulties and how cannabis use fits in.
Montreal, QuebecAges 16–80 - NCT05457140Recruiting
Testing genes and other samples in youth with first psychosis
This study looks at many types of tests (including genetic testing and other lab data) to help understand what may be causing first-time psychosis symptoms in youth. It may help doctors learn more about the condition for future care, and it can involve analyzing family genetic information.
San Diego, CaliforniaAges 7–17 - NCT05763966Recruiting
Uppsala study of psychosis risk and early psychosis
This study follows people with early psychosis, or a high risk of developing psychosis, to better understand brain and symptom changes over time. It may help future prevention or treatment by comparing brain/clinical measurements between people who are at risk, recently affected, and healthy controls.
UppsalaAges 18–40 - NCT05796401RecruitingPhase 3
Personalized care program for early psychosis outcomes
This trial tests whether a personalized care plan improves day-to-day functioning for people in the early stages of psychosis. It aims to see if adding structured support after a recent diagnosis can help you function better.
BrestAges 15–30 - NCT05813457Recruiting
Early identification program for first episode psychosis
This study checks whether finding and starting care early for a first episode of psychosis can shorten how long symptoms go untreated. You may be eligible if it’s your first episode and you haven’t been on antipsychotic medicines for long before now.
BronAges 15–35 - NCT05858255Recruiting
Exergaming program for people with psychosis
This study tests whether an “exergaming” exercise program (video games that make you move) can help people with schizophrenia-spectrum conditions. It’s meant to see if this kind of guided activity is safe and beneficial for symptoms and wellbeing.
Tønsberg, VestfoldAges 18–65 - NCT06036316Recruiting
Language and memory study for people with psychosis
This study looks at how language and memory interact in people with psychosis, including those at risk, early psychosis, or schizophrenia, as well as healthy volunteers. It aims to understand these connections better, which may help improve care.
Laxou, FranceAges 16–55 - NCT06107764Recruiting
Brain stimulation study for thinking and memory in psychosis
This trial tests whether a non-invasive brain stimulation technique (rTMS) can improve thinking and memory in people with psychosis. It involves MRI scans and several study visits at McLean Hospital.
Belmont, MassachusettsAges 18–55 - NCT06118268Recruiting
Brain stimulation to improve social thinking in psychosis
This study tests whether a type of brain stimulation called intermittent theta burst stimulation (iTBS) can help improve social thinking and understanding in people with psychosis. Researchers want to see if this treatment can boost how you read social cues and connect with others.
Glen Oaks, New YorkAges 18–39 - NCT06542640Recruiting
Understanding brain changes in youth at risk for psychosis
This research study looks at how the brain changes in young people who are at high risk for developing psychosis. It aims to find better ways to predict and prevent psychosis by using brain imaging and thinking tests.
Shanghai, Shanghai MunicipalityAges 15–35
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psychosis?
- Yes. Clin2 currently lists 145 recruiting psychosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psychosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psychosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.